1-4 of 4
Peter T. Tan, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, MBBS, MHS, Daniel A Pollyea, MD, Jacqueline S Garcia, MD, Andrew Brunner, MD, Fernando Roncolato, BMed, FRACP, FRCPA, Uma Borate, MD, Olatoyosi Odenike, MD, Ashish R. Bajel, FRACP, Anne Marie Watson, FRACP, FRCPA, MBBS, Katharina Götze, Florian Nolte, MD, Peter T. Tan, MBBS, Wan-Jen Hong, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Lori Gressick, BS, William Ainsworth, PhD, Jason Harb, PhD, Ahmed Hamed Salem, PhD FCP, John Hayslip, Ronan Swords, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 565.
https://doi.org/10.1182/blood-2019-124994
Published: 2019
Journal Articles

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, John Catalano, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Stephen Opat, MD, Nik Cummings, BSc, Andrew Spencer, MD
Journal: Blood
Blood (2011) 118 (21): 2599.
https://doi.org/10.1182/blood.V118.21.2599.2599
Published: 2011
Journal Articles

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Anthony P. Schwarer, MD, Elchanan H. Januszewicz, MBBS, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Wai Khoon Ho, MBBS FRACP FRCPA, Constantine S. Tam, MBBS, FRACP, FRCPA, Andrew Spencer, MD
Journal: Blood
Blood (2011) 118 (21): 3625.
https://doi.org/10.1182/blood.V118.21.3625.3625
Published: 2011
Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD
Journal: Blood
Blood (2011) 118 (21): 1529.
https://doi.org/10.1182/blood.V118.21.1529.1529
Published: 2011